Sonoma Pharmaceuticals, Inc.
SNOA
$1.33
$0.010.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.41M | 5.56M | 4.35M | 5.60M | 4.02M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.41M | 5.56M | 4.35M | 5.60M | 4.02M |
| Cost of Revenue | 3.83M | 3.38M | 2.70M | 3.48M | 2.55M |
| Gross Profit | 2.58M | 2.18M | 1.65M | 2.12M | 1.46M |
| SG&A Expenses | 2.02M | 1.99M | 1.77M | 1.88M | 1.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.45M | 5.91M | 5.03M | 5.94M | 5.11M |
| Operating Income | -40.00K | -351.00K | -678.00K | -337.00K | -1.10M |
| Income Before Tax | -330.00K | -497.00K | -949.00K | -731.00K | -1.24M |
| Income Tax Expenses | -- | 84.00K | -130.00K | -197.00K | -1.00K |
| Earnings from Continuing Operations | -330.00K | -581.00K | -819.00K | -534.00K | -1.24M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -330.00K | -581.00K | -819.00K | -534.00K | -1.24M |
| EBIT | -40.00K | -351.00K | -678.00K | -337.00K | -1.10M |
| EBITDA | -8.00K | -318.00K | -644.00K | -301.00K | -1.06M |
| EPS Basic | -0.09 | -0.33 | -0.48 | -0.32 | -0.76 |
| Normalized Basic EPS | -0.05 | -0.18 | -0.35 | -0.28 | -0.47 |
| EPS Diluted | -0.09 | -0.33 | -0.48 | -0.32 | -0.76 |
| Normalized Diluted EPS | -0.05 | -0.18 | -0.35 | -0.28 | -0.47 |
| Average Basic Shares Outstanding | 3.85M | 1.74M | 1.71M | 1.65M | 1.64M |
| Average Diluted Shares Outstanding | 3.85M | 1.74M | 1.71M | 1.65M | 1.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |